Cuộc họp công bố kết quả kinh doanh quý 3 năm 2026 của Fortrea (FTRE): Biên lợi nhuận mở rộng, nâng dự báo
Cuộc họp công bố kết quả kinh doanh quý 3/2026 của Fortrea ghi nhận doanh thu đạt 691,5 triệu USD, tăng trưởng EBITDA điều chỉnh 14,4%, dòng tiền mạnh mẽ hơn và nâng dự báo cho cả năm.
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.